Table 1.
Baseline characteristics and follow-up of the study population (n=934).
| Cohort characteristics | Total (n=934) |
|---|---|
| Recipient demographics | |
| Sex (male), n (%) | 571 (61.1) |
| Age (years), mean ± SD | 53.5 ± 13.2 |
| Repeat transplantation, n (%) | 141 (15.1) |
| Body mass index (kg/m2), mean ± SD | 25.4 ± 4.5 |
| Caucasian ethnicity, n (%) | 918 (98.3) |
| Cause of end stage renal disease | |
| Immune-mediated kidney diseases (IgA nephropathy, FSGS etc.), n (%) | 251 (26.9) |
| Cystic kidney disease | 176 (18.8) |
| Tubulointerstitial disease (TID) | 147 (15.7) |
| Chronic kidney disease (CKD) | 93 (10.0) |
| Diabetic nephropathy | 86 (9.2) |
| Vascular disease | 64 (6.9) |
| Hereditary kidney disease | 32 (3.4) |
| Other disease | 85 (9.1) |
| Donor demographics | |
| Sex (male), n (%) | 498 (53.3) |
| Age (years), mean ± SD | 47.6 ± 14.9 |
| Living donor, n (%) | 57 (6.1) |
| Donation after brain death, n (%) | 724 (77.5) |
| Donation after cardiac death, n (%) | 153 (16.4) |
| Cold ischaemia time (h), mean ± SD | 14.2 ± 5.7 |
| Transplant characteristics | |
| HLA-ABDRDQ antigen mismatches (0–8), mean ± SD | 3.4 ± 1.6 |
| Pretransplant total gamma globulins (g/L), mean ± SD | 11.0 ± 3.1 |
| Pretransplant anti-HLA antibodies, n (%) | 247 (26.4) |
| Pretransplant donor-specific HLA antibodies, n (%) | 108 (11.6) |
| MFI pretransplant donor-specific HLA antibodies, median (IQR) | 3125 (1345-6468) |
| Induction therapy, n (%) | 389 (41.6) |
| Immunosuppression regimen: TAC-MPA-CS, n (%) | 800 (85.7) |
| De novo donor-specific HLA antibodies, n (%) | 46 (4.9) |
| MFI de novo donor-specific HLA antibodies, median (IQR) | 2326 (1363-6449) |
| Median follow-up time post-transplant (years, IQR) | 8.1 (5.3 – 10.7) |
TAC, tacrolimus; MPA, mycophenolic acid; CS, corticosteroids; SD, standard deviation; IQR, interquartile range; MFI, median fluorescence intensity; FSGS, focal segmental glomerulosclerosis;